复合万古霉素海藻酸钠/壳聚糖缓释载体的体外释放研究  

Drug Releasing Test In Vitro of Sodium Alginate/Chitosan Incorporated With Vancomycin as Drug Delivery System

作　　者：李瑞欣[1] 马小军[2] 王卫明[1] 李诗荟[2] 王为[2] 赵德伟[1] 郭林[1] 于晓光[1] 

机构地区：[1]大连大学附属中山医院,辽宁大连116001 [2]中国科学院大连化学物理研究所,辽宁大连116001

出　　处：《中国医学工程》2010年第2期5-9,14,共6页China Medical Engineering

基　　金：大连市科技局青年基金(2004B3SF157);大连市科技局复合人才基金(2008J21JH001)资助;辽宁省自然科学基金(20062135)

摘　　要：目的探讨复合万古霉素海藻酸钠/壳聚糖(VCM/ACA)缓释系统中万古霉素缓释的动力学规律及影响因素。方法将万古霉素与海藻酸钠质量比分别为5:6和1:1的载体进行冷冻干燥处理和未冷冻干燥处理后制备成4组VCM/ACA载药载体。将载药载体放入pH7.2模拟体液PBS液中浸泡,通过测定浸泡液中万古霉素浓度,观察药物缓释的动力学规律和影响因素。结果 VCM/ACA载药载体的药物释放速度和释放量受载药量、调和比和冷冻干燥处理条件的影响。经冷冻干燥处理后调和比为1:1的载药载体可缓慢释药达250h以上。结论经过冷冻干燥处理万古霉素与海藻酸钠质量比(VCM:ALG)为1:1的载药载体体外能够稳定缓释万古霉素,可以满足临床实际需要。【Objective】To investigate the delayed releasing profile and different factors effected in vitro in course of Sodium Alginate/Chitosan incorporated with Vancomycin（VCM/ACA） releasing.【Methods】The VCM /ACA implants were divided into 4 groups depending on ratio of power to mixing solution（VCM：ALG = 5：6 or 1：1）,with or without freezing and drying.Then each group of VCM /ACA implants were putting in bottle dipping and to observe the releasing characteristic.【Results】VCM/ACA implants can last more than 250.1 hours.The releasing characteristic dependented on drug amount,mixing solution volme and the management.【Conclusion】The VCM/ACA（1：1） implants under the management of freezing and drying has remarkable relseasing profile,can use to satisfy the need of clinical.

关 键 词：海藻酸钠/壳聚糖 万古霉素 药物缓释系统 体外实验 

分 类 号：R965.1[医药卫生—药理学]